

Strategic Growth

Institutional Separately Managed Account (SMA)

Fact Sheet

September 30, 2024

The Eventide Strategic Growth Institutional SMA Strategy seeks long-term capital appreciation by investing primarily in equities of companies identified as having strong fundamentals, creating value for stakeholders (customers, employees, supply chain, community, environment and society), and trading at a discount to an estimate of fair value. Eventide’s proprietary Business 360® framework helps identify high-quality companies we believe are creating value for society, with excellent management teams and sustainable competitive advantages, in attractive industries. We seek resilient companies, whose long-term success is tied to their own ability to create value, rather than to macroeconomic and industry performance.

Trailing Returns² (%)

30 Sep 2024

Composite Performance	YTD	3-mos	1-year	3-year ³	5-year ³	10-year ³	Since Inception ³	Inception Date
Eventide Strategic Growth Institutional SMA–Gross	0.58	4.85	12.54	-4.96	10.41	11.64	14.23	08/01/2008
Eventide Strategic Growth Institutional SMA–Net	-0.02	4.64	11.64	-5.71	9.53	10.75	13.32	08/01/2008
<i>Benchmark</i>								
Bloomberg US Mid Cap Growth Index ⁴	12.64	8.09	27.45	3.34	11.84	11.08	10.73	08/01/2008

Calendar Year Returns² (%)

2014–2023

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Eventide Strategic Growth Institutional SMA–Gross	19.63	-0.83	2.27	34.67	-1.16	35.67	57.21	12.86	-33.18	24.12
Eventide Strategic Growth Institutional SMA–Net	18.68	-1.62	1.46	33.60	-1.95	34.59	55.95	11.96	-33.71	23.13
Bloomberg US Mid Cap Growth Index ⁴	12.55	-0.01	7.27	22.56	-6.00	34.34	32.06	18.73	-24.01	21.18

There is no guarantee that any investment strategy will achieve its objectives, generate profits, or avoid losses. Eventide’s values-based approach to investing may not produce desired results and could result in underperformance compared with other investments. Any reference to Eventide’s Business 360® approach is provided for illustrative purposes only and indicates a general framework of guiding principles that inform Eventide’s overall research process. Performance returns are displayed relative to an index. Investors cannot directly invest in an index, and unmanaged index returns do not reflect the application of any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Institutional SMA Strategy, and those who invest in an Institutional SMA should not expect identical returns to an index. Investing involves risk including the possible loss of principal. Past performance does not guarantee future results.

TOP HOLDINGS¹

Trane Technologies PLC (4.81%) HVAC systems for energy efficiency and reduced carbon emissions

Waste Connections Inc (4.42%) Differentiated waste services firm with servant leadership culture

Old Dominion Freight Line Inc (3.80%) Inter-regional and multi-regional motor carrier

DR Horton Inc (3.75%) Nationwide builder of affordable new homes

The Trade Desk Inc (3.45%) Digital advertising platform for display, social, and video campaigns

IDEXX Laboratories Inc (2.84%) Diagnostics for veterinary and water testing applications

Monolithic Power Systems Inc (2.60%) Power management solutions

Mettler-Toledo International Inc (2.53%) Weighing and analytical instruments and services

Roper Technologies Inc (2.50%) Software, water metering technologies, and medical products


Monday.com Ltd (2.34%) Cloud-based software for business workflow applications

- Does not include cash/money market funds/equivalents. Holdings based on the percentage of net assets of a representative account in the Strategic Growth Strategy, as of 09/30/2024. Eventide believes the representative account in the composite most closely reflects the current portfolio management style for the strategy. Performance is not a consideration in the selection of the representative account. Holdings information is subject to change at any time, and the holdings displayed may not accurately reflect the current composition of the representative account, or other accounts in the composite.
- Trailing returns are based on the composite returns of the Strategic Growth Strategy. Displayed returns do not reflect the deduction of taxes that an institutional investor would pay on transactions in an applicable account. Returns are as of the dates specified. Because of ongoing market volatility, the composite or an account within the composite may be subject to substantial short-term changes. As a result, current performance on a particular date of the composite or an account within the composite may differ from the performance returns shown.
- Performance figures for periods greater than 1 year are annualized. Annualized since inception figures use an inception date of 08/01/2008, the inception date of the Strategic Growth Strategy.
- The Bloomberg US Mid Cap Growth Index is a float market-cap-weighted index based on an equal-weighted combination of four factors: earnings yield, valuation, dividend yield, and growth. The constituents consist of the lower 800 in capitalization of the Bloomberg 1000 Index, which is a float market-cap-weighted benchmark of the 1000 most highly capitalized US companies.

OVERVIEW


Minimum Investment \$10m
 Fee Schedule (Annual Rate) 0.80% for \$0-25m; 0.70% for the next \$75m; 0.60% for over \$100m

Portfolio Composition¹ (%) 30 Sep 2024



Equity market capitalization: \$41.5B average, \$17B median
 Number of holdings: 59

Sector Allocation³ (%) 30 Sep 2024



Market Risk 30 Sep 2024

	Composite Std. Dev. 3-year	Composite Dispersion 3-year
Eventide Strategic Growth Composite	21.05	—
Bloomberg US Mid Cap Growth	20.26	—

- Source: © Morningstar, Inc. (2024). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
- Other might include cash equivalents, money market funds, or options on securities, as well as impact bonds used to fund business models that strive to have significant social or environmental effects.
- Allocation percentages are based on the allocation of a representative account in the Strategy on the last day of the applicable quarter. They may or may not accurately reflect the allocations in other accounts in that Strategy at the end of the quarter, or the allocations in the representative account on the current date. Allocations are subject to change at any time. Allocations should not be considered investment advice.

Application of Eventide's values-based screening criteria could cause the Strategic Growth Strategy to underperform similar strategies that do not have such screening criteria. This could be due to ethically acceptable companies falling out of favor with investors or failing to perform as well as companies that do not meet Eventide's values-based screening guidelines. Investing in the Strategic Growth Strategy involves risk, including the possible loss of principal. The Strategic Growth Strategy can invest in biotechnology and pharmaceutical companies, which present risks including that they may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Strategic Growth Strategy can invest in technology companies, which present risks including the company's products becoming obsolete and entrance of competing products. The Strategic Growth Strategy can invest in companies in the industrial sector which presents risks including risk related to debt loads, intense competition, and sensitivity to economic cycles. Risks associated with investments in foreign companies include exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. ADRs are certificates that evidence ownership of shares of a foreign company and are alternatives to purchasing foreign securities directly in their national markets and currencies. ADRs are generally subject to the same risks as direct investment in foreign companies. The Strategic Growth Strategy can invest in the stocks of smaller-sized and mid-sized companies, which generally have earnings and prospects that vary more volatile than larger companies. These companies may experience higher failure rates than larger companies. Small- and

mid-sized companies normally have a lower trading volume than larger companies, which may tend to make their market price fall more disproportionately than larger companies in response to selling pressures. Small- and mid-sized companies may also have limited markets, product lines or financial resources and may lack management experience. "Growth" stocks can react differently to issuer, political, market, and economic developments than the market as a whole and other types of stocks, and present unique risks.

Investors should consider the Strategic Growth Strategy's investment objectives, risks, charges, and expenses carefully before investing or sending money. Investors should also carefully review a current copy of Eventide's Brochure for an additional disclosure of Eventide's investment strategies, approach, and relevant risks, as updated from time to time. For more information, please contact Eventide at 1-877-771-EVEN (3836).

MANAGER



Finny Kuruvilla, MD, PhD, serves as Co-Chief Investment Officer and Senior Portfolio Manager for Eventide. He serves as the Lead Portfolio Manager for Eventide's Strategic Growth, Healthcare & Life Sciences, and Technology Strategies. He also is a Managing Director for Eventide Ventures, as well as a Founding Member of Eventide. Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women's Hospital and Boston Children's Hospital, where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, an SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.

Eventide Asset Management, LLC
 One International Place, Suite 4210
 Boston, MA 02110
 877-771-EVEN (3836)
WWW.EVENTIDEINVESTMENTS.COM